Neuromyelitis optica spectrum disorder has long been distinguished from multiple sclerosis by its serological signature. In 2004, Lennon and colleagues identified a serum autoantibody that marks the disease and separates it clearly from multiple sclerosis, an antibody directed against aquaporin-4, a water channel protein abundantly expressed on astrocytes at the blood-brain barrier and within the central nervous system parenchyma. The binding of these pathogenic immunoglobulin G antibodies to aquaporin-4 triggers complement activation, inflammatory injury to astrocytes, and secondary damage to neurons and oligodendrocytes. Because the antibody is produced by B lineage cells, the logical therapeutic strategy has been to deplete the cells that generate it.

That strategy has been validated repeatedly. Rituximab, a chimeric monoclonal antibody targeting CD20 on the surface of pre-B cells and mature B cells, entered clinical practice on the strength of open-label series and was later tested in the RIN-1 study, a multicentre, randomised, double-blind, placebo-controlled trial published in The Lancet Neurology in 2020, which established its safety and efficacy in the disorder. Inebilizumab, a humanized anti-CD19 antibody with a broader reach across the B cell lineage because it also targets plasma cell precursors, demonstrated benefit in the N-MOmentum phase 2/3 trial reported in The Lancet in 2019. Complement inhibition with eculizumab, reported in the New England Journal of Medicine in 2019, provided an alternative downstream approach by blocking the terminal complement pathway that the pathogenic antibodies engage.

Now obinutuzumab β, a glycoengineered type II anti-CD20 monoclonal antibody, has produced remarkable results in a phase 3 randomized controlled trial described by Wu and colleagues in Nature Medicine. Unlike type I anti-CD20 antibodies such as rituximab, type II antibodies like obinutuzumab engage CD20 in a manner that promotes direct cell death through non-apoptotic mechanisms and mediates more efficient depletion of certain B cell compartments, including tissue-resident populations that are less accessible to complement-dependent mechanisms. The glycoengineering of the Fc region enhances affinity for activating Fc gamma receptors on effector cells, sharpening antibody-dependent cellular cytotoxicity. These pharmacological distinctions matter, because the depth of depletion achieved within different B cell niches may determine how thoroughly autoantibody production is suppressed.

This is precisely the distinction Nakashima highlights in his analysis. The pathogenic anti-aquaporin-4 antibodies in neuromyelitis optica spectrum disorder are secreted by plasmablasts and plasma cells, differentiated descendants of B cells that express little or no surface CD20 and are therefore invisible to all anti-CD20 therapies. Yet clinical experience shows that depleting CD20-positive B cells nevertheless suppresses disease activity in most patients, implying that the continuously replenished pool of CD20-positive B cells is essential for sustaining the plasmablast population that secretes the pathogenic antibody. Fundamental work by Chihara and colleagues, published in the Proceedings of the National Academy of Sciences in 2011, showed that interleukin-6 signaling promotes anti-aquaporin-4 autoantibody production from plasmablasts, suggesting that the survival and differentiation of antibody-secreting cells depend on signals delivered by the surrounding B cell and immune milieu that anti-CD20 therapy disrupts.

The deeper-versus-broader framing also captures a paradox that clinicians have observed since the earliest rituximab era. Nakashima himself reported, in the Journal of Clinical Neuroscience in 2011, transient increases in anti-aquaporin-4 antibody titers following rituximab treatment, associated with elevated serum levels of BAFF, a B cell activating factor belonging to the tumour necrosis factor family. When B cells are depleted, BAFF levels rise because the cytokine is no longer consumed by its targets, and this surge can paradoxically promote the differentiation of surviving precursors towards antibody-secreting cells. Perumal and colleagues documented disease exacerbation after rituximab induction in a subset of patients, a phenomenon plausibly linked to these humoral dynamics. Any new depleting agent must therefore be evaluated not only for how deeply it depletes circulating B cells but also for how it perturbs the regulatory cytokine networks that govern reconstitution.

Dysregulated B cell differentiation towards antibody-secreting cells is now recognised as a hallmark of the disease, as Hoshino and colleagues described in the Journal of Neuroinflammation in 2022. In patients with neuromyelitis optica spectrum disorder, the balance between naïve B cells, memory compartments, and plasmablasts is shifted, with expanded populations of antibody-secreting cells circulating in the blood and correlating with disease activity. This pathobiology explains why broader depletion strategies, such as those targeting CD19 across a wider span of B cell differentiation including plasmablast precursors, and deeper depletion strategies, such as those using type II anti-CD20 antibodies with enhanced effector function, both hold mechanistic appeal. The phase III results with obinutuzumab β suggest that the depth and character of depletion may translate directly into clinical protection against relapse, the outcome that matters most in a disease where each attack can leave permanent, disabling neurological damage.

The clinical stakes of these distinctions are considerable. Neuromyelitis optica spectrum disorder disproportionately affects women and shows a striking predilection for populations in East Asia, and attacks of optic neuritis and transverse myelitis can cause irreversible blindness and paralysis. Since the identification of the aquaporin-4 antibody, a growing therapeutic armamentarium has emerged, encompassing B cell depletion, complement inhibition, and blockade of the interleukin-6 receptor, each intercepting the autoimmune cascade at a different point. The demonstration that obinutuzumab β achieves striking efficacy adds a potent new option, but it also invites head-to-head comparisons that have not yet been performed, leaving open the question of whether deeper depletion of conventional B cell compartments truly outperforms broader depletion that extends into the plasmablast lineage.

Longer-term considerations also come into focus as depleting therapies mature. Repeated courses of B cell depletion carry implications for humoral immunity, vaccine responses, and infection risk, and the dynamics of B cell reconstitution after obinutuzumab β, with its enhanced potency, may differ meaningfully from those seen after rituximab or inebilizumab. Monitoring strategies based on circulating CD19 and CD27-positive cell counts, serum BAFF levels, and anti-aquaporin-4 antibody titers may ultimately allow clinicians to individualise retreatment intervals, depleting deeply enough to prevent relapse while avoiding the prolonged immunosuppression that extended courses might otherwise impose. Biomarker-driven personalisation of this kind remains aspirational, but the mechanistic groundwork laid over the past two decades makes it increasingly plausible.

What the phase III obinutuzumab β trial ultimately delivers, in Nakashima’s assessment, is both a confirmation and a challenge. The confirmation is that B cell depletion remains the most reliable therapeutic principle yet discovered for aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder, capable of preventing the relapses that define the disease’s destructive course. The challenge is to move beyond the blunt question of whether B cells should be depleted and toward the precise one of which subpopulations sustain the autoimmune process, and how the depth, breadth, and timing of depletion can be tuned to maximize benefit while minimizing risk. As next-generation antibodies push the limits of what depletion can achieve, the field is converging on a richer, more granular understanding of B cell biology in neuroimmunological disease, one in which the architecture of the humoral immune response, rather than its mere suppression, becomes the true target of therapy.

Subject of Research: B cell depletion therapy for aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder

Article Title: Deeper versus broader B cell depletion in neuromyelitis optica spectrum disorder

Article References: Nakashima, I. (2026). Deeper versus broader B cell depletion in neuromyelitis optica spectrum disorder. Nature Reviews Neurology. https://doi.org/10.1038/s41582-026-01269-w

Image Credits: AI Generated

DOI: 10.1038/s41582-026-01269-w

Keywords: neuromyelitis optica spectrum disorder, B cell depletion, obinutuzumab beta, aquaporin-4 antibody, anti-CD20 therapy, plasmablasts, rituximab, inebilizumab, neuroimmunology, phase III trial, BAFF, autoantibody

The condition is associated with antibodies directed against myelin oligodendrocyte glycoprotein, a protein located on the outer surface of oligodendrocytes and the myelin sheath. MOG-IgG testing is therefore central to diagnosis, but the presence of an antibody alone does not automatically establish that a patient has MOGAD. Low-positive results can occur in people with other neurological conditions, and test performance varies according to the laboratory method, the antibody threshold and the clinical population being tested. The 2023 criteria were developed to address this problem by combining a compatible demyelinating event with MOG-IgG detection and additional clinical or radiological features that strengthen the diagnosis.

The new analysis brought together evidence from studies that assessed the criteria in two broad types of patient population. The first consisted of broad diagnostic-evaluation cohorts, in which individuals were investigated for a range of inflammatory, infectious, vascular and degenerative neurological disorders. The second included MOG-IgG-positive enriched cohorts, which contained a much larger proportion of patients already suspected of having MOGAD or known to carry the antibody. Separating these groups is technically essential. Diagnostic accuracy can appear exceptionally high when a test is examined in a population enriched with classic cases, whereas performance may be more demanding and clinically relevant when the same criteria are applied to patients whose symptoms and test results are less clear.

Across the available evidence, the 2023 criteria demonstrated strong diagnostic performance, supporting their use as a practical international standard. Their principal strength was the ability to identify patients with a characteristic demyelinating syndrome while requiring laboratory and clinical evidence that the antibody finding was meaningful. The analysis also indicated that performance was not uniform across all settings. Results were generally more favorable in enriched cohorts, where the pre-test probability of MOGAD was high, while broad diagnostic cohorts exposed the greater difficulty of distinguishing genuine disease from incidental or nonspecific MOG-IgG positivity. This difference does not necessarily weaken the criteria; rather, it shows why diagnostic interpretation must include the clinical context in which testing is performed.

The distinction between sensitivity and specificity is central to understanding the findings. Sensitivity describes the proportion of true MOGAD cases correctly recognized by the criteria, while specificity measures how effectively the criteria exclude patients who do not have the disease. A highly sensitive system reduces the risk of missed diagnoses, which is important because untreated attacks can leave permanent visual, motor or cognitive impairment. High specificity is equally important because MOGAD is treated with immunotherapies that may expose patients to infection and other complications. Misclassification can also lead to inappropriate long-term treatment, particularly when MOGAD is confused with multiple sclerosis or neuromyelitis optica spectrum disorder, conditions that may require different therapeutic strategies.

The panel’s framework reflects the biological complexity of MOGAD. In patients with strongly positive serum results obtained through validated cell-based assays, a compatible clinical syndrome may provide substantial diagnostic support. In contrast, weak-positive results demand greater caution and a closer search for supportive features. These may include bilateral or markedly swollen optic neuritis, longitudinally extensive myelitis, an acute disseminated encephalomyelitis-like presentation, distinctive brain lesions or a pattern of recovery that is more typical of MOGAD than of competing diagnoses. The criteria also emphasize that MOG-IgG should be interpreted in serum rather than relying primarily on cerebrospinal fluid, because serum testing is generally more sensitive for detecting the relevant antibody response.

The meta-analysis highlights a persistent challenge in antibody-based neurology: the meaning of a laboratory result depends on the patient population and the assay used. Live cell-based assays are designed to present native MOG on the surface of cells, allowing antibodies to bind the protein in a configuration closer to that found in human tissue. However, different platforms, cut-off values and laboratory procedures can produce different results. The likelihood that a positive result represents true disease is also influenced by prevalence. In a specialist MOGAD clinic, a positive result may have a high positive predictive value; in a general neurology service testing many patients with atypical symptoms, the same result may be less decisive.

For clinicians, the findings reinforce a stepwise approach rather than an antibody-first diagnosis. Physicians must first determine whether the patient has a recognizable central nervous system demyelinating event. They must then evaluate the strength and reliability of the MOG-IgG result, review magnetic-resonance imaging and consider alternative diagnoses, including multiple sclerosis, aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder, infection, ischemia and malignancy. The criteria are therefore best understood as a structured diagnostic safeguard. They organize evidence and reduce inconsistency, but they do not replace expert judgment, especially in patients with low antibody titers, atypical symptoms or a clinical course that does not fit the usual spectrum of MOGAD.

The study also carries implications for future research and clinical trials. Reliable case definitions are necessary for comparing treatment outcomes, estimating relapse risk and determining whether a therapy prevents disability. If different research groups enroll patients using incompatible diagnostic standards, apparently conflicting findings may simply reflect differences in patient selection. By testing the 2023 criteria across broad and enriched cohorts, the review provides a clearer picture of where the framework performs well and where additional validation is needed. Future studies will likely focus on children, patients with isolated seizures or cognitive symptoms, individuals with borderline antibody results and populations from regions where access to specialized testing remains limited.

The overall message is one of confidence tempered by caution. The 2023 International MOGAD Panel criteria offer a robust and clinically useful method for diagnosing a disease that was frequently hidden within broader categories of inflammatory demyelination. Their high performance across evaluated cohorts supports wider adoption, while the differences between broad and antibody-enriched populations demonstrate why test results must never be interpreted in isolation. As MOGAD recognition expands, combining a compatible neurological syndrome, validated antibody testing, supportive imaging and rigorous exclusion of alternatives will remain the safest route to accurate diagnosis and timely treatment.

Subject of Research: Diagnostic performance of the 2023 International MOGAD Panel criteria for identifying myelin oligodendrocyte glycoprotein antibody-associated disease.

Article Title: Diagnostic performance of the 2023 International MOGAD Panel criteria in broad diagnostic-evaluation and MOG-IgG-positive enriched cohorts: a systematic review and meta-analysis

Article References: Journal of Neurology, Springer Nature, article associated with DOI 10.1007/s00415-026-14079-3.

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14079-3

Keywords: MOGAD, MOG-IgG, myelin oligodendrocyte glycoprotein, autoimmune demyelination, optic neuritis, transverse myelitis, diagnostic criteria, systematic review, meta-analysis, neuroimmunology.

Mycoplasma pneumoniae, a unique bacterium lacking a cell wall, is well-known for its role in respiratory infections, particularly among children and young adults. Unlike traditional bacterial pathogens, Mycoplasma pneumoniae can lead to a range of clinical manifestations, including atypical pneumonia and extrapulmonary complications. Though generally self-limiting, its infections have been linked to autoimmune phenomena, prompting researchers to investigate the underlying mechanisms that associate this pathogen with immune-mediated conditions such as NMOSD.

Neuromyelitis optica spectrum disorder is characterized by significant and debilitating effects on the central nervous system, most notably the optic nerves and spinal cord, and is often marked by severe episodes of inflammation and demyelination. Aquaporin-4 (AQP4) antibodies are present in a significant number of NMOSD cases, aiding in the differentiation of this disorder from multiple sclerosis and other similar conditions. The binding of these antibodies to AQP4, a water channel protein found in astrocytes, leads to the destruction of host cells and results in the distinctive symptomatic picture seen in affected individuals.

The case outlined by Liang et al. involves a patient who developed NMOSD symptoms following an acute Mycoplasma pneumoniae infection. This case serves as a poignant example of how a seemingly benign respiratory pathogen can initiate a cascade of immune responses, culminating in severe neurological dysfunction. The patients’ clinical features, along with laboratory findings that confirmed the presence of AQP4 antibodies, underscore the importance of considering NMOSD when faced with neurological symptoms post-infection.

Investigations into the pathophysiological mechanisms underlying this intersection reveal a fascinating interplay between infection and autoimmunity. The activation of autoreactive T cells during a Mycoplasma pneumoniae infection can inadvertently trigger an autoimmune response against self-antigens, such as AQP4. This phenomenon suggests a potential viral mimicry or bystander activation, where the immune system, in its fervor to combat the pathogen, mistakenly targets host cells expressing similar antigens.

To date, there has been limited literature discussing the direct association between Mycoplasma pneumoniae infections and NMOSD. However, the evidence presented in this case report, along with the authors’ thorough literature review, emphasizes an urgent need for further research. The rarity of such cases does not imply that the association does not exist; rather, it points to the complexity and variability of immune responses and the potential for underdiagnosis in clinical settings.

The implications of this research extend beyond the individual case presented. It highlights crucial aspects of patient management, including the need for heightened awareness among clinicians treating individuals with respiratory infections. Early recognition of neurological symptoms and subsequent investigations could facilitate timely diagnosis of NMOSD, which is critical for effective management and can drastically alter the trajectory of the disease.

Treatment strategies for NMOSD, particularly when secondary to infections like those caused by Mycoplasma pneumoniae, may necessitate a multifaceted approach. Immunotherapy, often a cornerstone of NMOSD management, must be balanced with the need to treat the underlying infection. This dual consideration complicates treatment protocols but underscores the necessity for collaboration among infectious disease specialists and neurologists.

Moreover, the findings call for the establishment of clinical guidelines to aid in the recognition and referral of patients developing neurological symptoms after respiratory infections. These guidelines must include recommendations for serological testing for AQP4 antibodies in appropriate scenarios, thus potentially streamlining the diagnostic process for NMOSD.

A breakthrough in understanding the relationship between an infection and an autoimmune disorder such as NMOSD may pave the way not only for more effective therapeutic approaches but also for preventive strategies. Vaccination against Mycoplasma pneumoniae, while not currently available, could emerge as a topic for future research endeavors.

In conclusion, the report from Liang, Chen, and Zheng contributes significantly to the literature on infectious diseases and autoimmunity. It serves as a crucial reminder of the intricate relationships that exist within the human body and how an infection can dramatically alter immune dynamics. As we advance our understanding of these connections, the potential for improved diagnosis and treatment increases, heralding a future where knowledge translates into better patient outcomes.

This case report stands as a clarion call for medical professionals to maintain a high index of suspicion for rare but significant complications following common infections. As research continues to unfold in this field, the hope is that such cases will inform clinical practice, guiding effective management and ultimately improving quality of care for affected individuals.

In summary, the exploration of the nuances between infectious agents and autoimmune responses represents an essential frontier in medical research. The case of Mycoplasma pneumoniae infection precipitating NMOSD is a vivid illustration of the complexities involved in these conditions and serves as an impetus for ongoing investigation.

Subject of Research: The relationship between Mycoplasma pneumoniae infection and aquaporin-4-positive neuromyelitis optica spectrum disorder.

Article Title: Mycoplasma pneumoniae infection and concurrent aquaporin-4-positive neuromyelitis optica spectrum disorder: a case report and literature review.

Article References:

Liang, H., Chen, Y. & Zheng, P. Mycoplasma pneumoniae infection and concurrent aquaporin-4-positive neuromyelitis optica spectrum disorder: a case report and literature review.
BMC Pediatr 25, 765 (2025). https://doi.org/10.1186/s12887-025-06155-w

Image Credits: AI Generated

DOI: 10.1186/s12887-025-06155-w

Keywords: Mycoplasma pneumoniae, neuromyelitis optica spectrum disorder, aquaporin-4, autoimmune response, respiratory infections, case report.